BPC
SLNO

Bryce Point Capital’s Soleno Therapeutics SLNO Stock Holding History

Bryce Point Capital’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,243
Closed -$233K – 261
2025
Q1 		$233K Sell
3,243
-10,559
-77% -$514K 0.18% 159
2024
Q4 		$620K Buy
+13,802
New +$715K 0.18% 159

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Bryce Point Capital's SLNO Position: Q2 2025 in Review

Bryce Point Capital sold out of Soleno Therapeutics (SLNO) in Q2 2025, closing a stake of 3,243 shares — an estimated $233K sold.

Bryce Point Capital first reported a position in SLNO in Q4 2024 and held it in 2 quarters. The position peaked at $620K in Q4 2024. 233 funds tracked by Wall St. Rank hold SLNO as of Q2 2025.

  • Bryce Point Capital reported no remaining Soleno Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bryce Point Capital sold 3,243 Soleno Therapeutics shares in Q2 2025, an estimated $233K.
  • Bryce Point Capital first reported a position in Soleno Therapeutics in Q4 2024 and held it in 2 quarters.
  • Bryce Point Capital's Soleno Therapeutics position peaked at $620K in Q4 2024.
  • 233 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2025.

Based on Bryce Point Capital's 13F filing for Q2 2025, filed 5 Aug 2025.